Lexeo Therapeutics Early Phase Trial for Friedreich Ataxia Cardiomyopathy Drug Shows Improvements in Cardiac Biomarkers
Lexeo Therapeutics Early Phase Trial for Friedreich Ataxia Cardiomyopathy Drug Shows Improvements in Cardiac Biomarkers
Lexeo Therapeutics針對Friedreich運動失調心肌病藥物的早期試驗顯示心臟生物標誌物有所改善。
Unity Software(U.US) reported fourth-quarter financial results after the market close on Monday. Here's a rundown of the report.Q4 Earnings: Unity said fourth-quarter revenue increased 35% year-over-year to $609 million, beating the consensus estimate of $562.71 million. The company reported a quarterly loss of 66 cents per share.
登入免費觀看全文
登入/註冊